Levophacetoperane (Lidépran, Phacétoperane) is a psychostimulant developed by Rhône-Poulenc in the 1950s.[1] The drug has been used as an antidepressant and anorectic.[2][3] It is the reverse ester of methylphenidate. Phacetoperane and levophacetoperane have been used as wakefulness-promoting agents in the treatment of narcolepsy.[4]
The precursor is called Phenyl(piperidin-2-yl)methanol. This same chemical was used in the synthesis of a compound that is called WV-1501 [5712-28-7],[5][6] which is closely related to aminorex.
↑Marie JN, Michel JR, "New esters", US patent 2928835, published 15 March 1960, assigned to Rhône-Poulenc
↑"Isolation and detection of methylphenidate, phacetoperane and some other sympatomimetic central nervous stimulants with special reference to doping. I. Gas chromatographic detection procedure with electron capture detection for some secondary amines". Journal of Chromatography106 (2): 412–7. March 1975. doi:10.1016/S0021-9673(00)93853-6. PMID239015.
↑Konofal E, Figadere B, "Phacetoperane for the treatment of attention-deficit hyperactivity disorder", US patent 20150038533, published 5 February 2015, assigned to Assistance Publique – Hôpitaux de Paris
↑"From past to future: 50 years of pharmacological interventions to treat narcolepsy". Pharmacol Biochem Behav241. August 2024. doi:10.1016/j.pbb.2024.173804. PMID38852786.
↑Kroneberg Dr Hans-Guenther, et al. GB995964 (1965 to Bayer AG).
↑European Journal of Medicinal Chemistry--Chimie Therapeutique., 15(111), 1980.
